Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer.

Nature communications·2026
Same author

Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation.

Clinical and experimental immunology·2026
Same author

Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells.

British journal of cancer·2026
Same author

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.

Biology·2025
Same author

Multidisciplinary Prehabilitation Reduces Hospitalization Time and Suggests Improved Survival in Patients with Radiologically Diagnosed Lung Cancer.

Cancers·2025
Same author

CAR-T cell technologies that interact with the tumour microenvironment in solid tumours.

Expert review of clinical immunology·2024

Related Experiment Video

Updated: Mar 29, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K

Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.

Benjamin J L Lim1, John Maher2,3,4

  • 1University of Edinburgh Medical School, University of Edinburgh, Little France Crescent, Edinburgh EH16 4UU, UK.

Cells
|March 27, 2026
PubMed
Summary

Gamma delta (γδ) T cells offer a promising alternative for cancer immunotherapy, overcoming limitations of current CAR T cell therapies. Research explores enhancing their anti-tumour activity and clinical applications for improved cancer treatment.

Keywords:
chimeric antigen receptorimmunotherapymalignancyγδ T cell

More Related Videos

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product
11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

10.1K
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

1.1K

Related Experiment Videos

Last Updated: Mar 29, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K
Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product
11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

10.1K
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

1.1K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Adoptive immunotherapy with autologous alpha-beta (αβ) T cells, particularly chimeric antigen receptor (CAR) T cells, has transformed hematological cancer treatment.
  • Limitations of autologous CAR T cell therapy include poor scalability and limited efficacy against solid tumors.
  • Alternative T cell populations are needed to address these challenges in cancer immunotherapy.

Purpose of the Study:

  • To evaluate the potential of gamma delta (γδ) T cells as an alternative for cancer immunotherapy.
  • To explore how manufacturing and genetic engineering can enhance γδ T cell anti-tumour activity.
  • To summarize current clinical data on CAR γδ T cell therapies and discuss future directions.

Main Methods:

  • Review of existing literature on γδ T cell biology and function in cancer.
  • Analysis of strategies for ex-vivo expansion and genetic modification of γδ T cells.
  • Summary of clinical trial data for chimeric antigen receptor γδ (CAR γδ) T cell therapies.

Main Results:

  • γδ T cells possess intrinsic anti-tumour activity and do not cause graft-versus-host disease (GvHD) when used allogeneically.
  • Manufacturing and genetic engineering advancements can significantly potentiate the anti-cancer efficacy of γδ T cells.
  • Early clinical studies show promise for CAR γδ T cell therapies in treating various cancers.

Conclusions:

  • γδ T cells represent a viable and potentially superior alternative to αβ T cells for allogeneic cell-based cancer immunotherapy.
  • Further development of CAR γδ T cell technology holds significant promise for next-generation cancer treatments, especially for solid tumors.
  • Optimized manufacturing and engineering are crucial for realizing the full therapeutic potential of γδ T cell-based immunotherapies.